AnalystsInsight

Jeff Jones (Oppenheimer): Analyst Track Record and Price‑Target Accuracy

How often Jeff Jones’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 520 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Jeff Jones ranks #893 of 1,000 analysts in Exent’s scoring (4.5★).
  • 21.1% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 135 days; 33.1% of calls were up 12 months later.
  • Most‑covered stocks: CATX, CRBP, ALMS, CMMB.
  • Free on Exent: Jeff Jones’s full record, with ratings 3 days after publication.

Jeff Jones’s track record at a glance

Jeff Jones of Oppenheimer ranks #893 of the 1,000 analysts Exent scores, with a 4.5★ rating and a focus on healthcare. Over a 7‑year lookback, 21.1% of Jeff’s price targets were reached, 31.3 points below the 52.4% average across all analysts.

MetricJeff JonesAll analysts
Price‑target hit rate21.1%52.4%
Median days to hit target135 days91 days
Calls up after 12 months33.1%64.0%
Median 12‑month return of calls−25.4%+13.4%
Hit rate, last 2 years14.7%—
Average worst drop after a call−42.1%—
Ratings in the sample520—
Stocks covered31—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetJeff Jones
Under 30 days14.0%
30–90 days16.3%
90–180 days32.6%
Over 180 days37.2%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Jeff Jones covers most

StockRatings in the sample
CATX47
CRBP36
ALMS30
CMMB27
PHVS24
CLRB24
CRVS21
KYMR21

In the past year Jeff’s ratings were 98% Buy, 2% Hold and 0% Sell.

Jeff Jones’s latest ratings

DateStockActionRatingPrice target
Sep 9, 2026AKTSInitiated Coverage: BuyBuy$40.00
Sep 8, 2026PHVSReiterated: BuyBuy$75.00
Sep 2, 2026ALMSReiterated: BuyBuy$37.00
Sep 1, 2026PMVPReiterated: BuyBuy$5.00
Aug 21, 2026AAPGReiterated: BuyBuy$45.00
Aug 17, 2026PMVPReiterated: BuyBuy$5.00
Aug 14, 2026MDWDReiterated: BuyBuy$30.00
Aug 14, 2026ALMSReiterated: BuyBuy$55.00
Aug 14, 2026PTHSReiterated: BuyBuy$64.00
Aug 13, 2026ACRVReiterated: BuyBuy$8.00
Aug 13, 2026PHVSReiterated: BuyBuy$50.00
Aug 13, 2026AVBPReiterated: BuyBuy$50.00
  • Sep 9, 2026
    Stock
    AKTS
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $40.00
  • Sep 8, 2026
    Stock
    PHVS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $75.00
  • Sep 2, 2026
    Stock
    ALMS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $37.00
  • Sep 1, 2026
    Stock
    PMVP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $5.00
  • Aug 21, 2026
    Stock
    AAPG
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $45.00
  • Aug 17, 2026
    Stock
    PMVP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $5.00
  • Aug 14, 2026
    Stock
    MDWD
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $30.00
  • Aug 14, 2026
    Stock
    ALMS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $55.00
  • Aug 14, 2026
    Stock
    PTHS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $64.00
  • Aug 13, 2026
    Stock
    ACRV
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $8.00
  • Aug 13, 2026
    Stock
    PHVS
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $50.00
  • Aug 13, 2026
    Stock
    AVBP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $50.00

Jeff’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Jeff Jones’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Jeff Jones ranks #893 of 1,000 with a 4.5★ rating. 21.1% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 33.1% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Jeff Jones’s success rate is 41.8% by the ranking source and 21.1% by Exent’s price-target hit-rate backtest, with a median of 135 days to reach a target.

Jeff Jones (Oppenheimer) covers 31 stocks, mostly in healthcare. The most frequently rated are CATX, CRBP, ALMS, CMMB, PHVS.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.